Klaus has more than 30 years of experience in nonclinical drug development, preclinical safety testing and assessment of both small molecule and large molecule drugs of different formats, as well as of industrial chemicals and medical devices. Most recently he served as Senior Director Non-Clinical Innovation and R&D Strategy at Shire, previously Baxalta. Before he was Vice President Drug Safety at Thesan Pharmaceuticals in Carlsbad, CA, a dermatology development company, and Vice President Preclinical Development at Berg Health, Framingham, MA; he represented Nonclinical Safety at the Novartis Biotherapeutics Development Unit in San Diego, CA. Dr. Krauser is experienced in leading large teams, i.e. Global Preclinical Safety at Abbott, Global Toxicology at Merck/EMD Serono, Geneva, Switzerland, and Short- and Long-Term Toxicology at Schering AG (now Bayer) in Berlin, Germany. He also directly supported study and project activities in small to medium sized companies, i.e. Arena Pharmaceuticals, the developer of the obesity drug Lorcaserin (Belviq®), and ASTA Medica AG in Frankfurt, Germany, the inventor of Cyclophosphamide (Endoxan®). Dr. Krauser contributed to numerous INDs and CTAs as well as global marketing authorization filings (NDAs, BLAs), e.g. Humira®, TriCor®, Xience® coronary stents, Betaseron®, Yasmin®, Magnevist®, Belviq®, Erbitux®, new Rebif® formats, Astelin®, Optivar®, Ifex®, Impavido®, Cetrotide®. Klaus studied Veterinary Medicine at the Freie Universitaet in Berlin, Germany, from where he also received his PhD in Veterinary Pathology. He is a Diplomate of the European College of Veterinary Pathologists and German Board Certified in Veterinary Pathology and Toxicopathology as well as in Pharmacology and Toxicology.